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Transient receptor potential (TRP) channels belong to the
most intensely pursued drug targets of the last decade. These
ion channels are considered promising targets for the
treatment of pain, hypersensitivity disorders and lower
urinary tract symptoms (LUTS). The aim of the present
review is to discuss to what extent TRP channels have
adhered to their promise as new pharmacological targets in
the lower urinary tract (LUT) and to outline the challenges
that lie ahead.
• TRP vanilloid 1 (TRPV1) agonists have proven their eﬃcacy
in the treatment of neurogenic detrusor overactivity (DO),
albeit at the expense of prolonged adverse eﬀects as pelvic
‘burning’ pain, sensory urgency and haematuria.
• TRPV1 antagonists have been very successful in preclinical
studies to treat pain and DO. However, clinical trials with
the ﬁrst generation TRPV1 antagonists were terminated
early due to hyperthermia, a serious, on-target, side-eﬀect.
• TRP vanilloid 4 (TRPV4), TRP ankyrin 1 (TRPA1) and TRP
melastatin 8 (TRPM8) have important sensory functions in
the LUT. Antagonists of these channels have shown their
potential in pre-clinical studies of LUT dysfunction and are
awaiting clinical validation.
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Introduction: Transient Receptor
Potential (TRP) Channels as Therapeutic
Targets in Functional Lower Urinary Tract
(LUT) Disorders
TRP channels constitute a large superfamily of cation selective
channels. The human TRP family consists of 27 members
that are divided in six subfamilies: TRPC (canonical), TRPV
(vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML
(mucolipin) and TRPA (ankyrin) [1].
A particular characteristic of these ubiquitously expressed
channels is that a wide range of physical and chemical stimuli
can regulate their activation. Thus, TRP channels can act as
polymodal cellular sensors that are involved in numerous
sensory and homeostatic processes. Recent research has shown
the involvement of TRP channels in numerous physiological
processes and in the ontogeny of hereditary and acquired
diseases [1]. Therefore, TRP channels represent a promising
class of pharmacological targets for various pathological
conditions.
TRP channels in the LUT have been increasingly studied
over the last decade. Their (patho)physiological role in LUT
(dys)function is slowly being deciphered and some of them
are considered attractive targets for pharmacotherapy of
LUT dysfunction. TRP channels that function as cellular
sensors in the bladder wall can directly be targeted to
modulate mechanosensation (feelings or urge or urgency),
pain perception (suprapubic pain, mictalgia . . .) and/or
thermosensation (‘burning’ sensations, bladder cooling reﬂex).
Alternatively, these proteins can be targeted to alter the
function (excitability) of sensory nerves that send aﬀerent
information from the LUT to the CNS. Growing evidence
suggests that these aﬀerent neural pathways are at least as
important as eﬀerent ortho- and parasympathetic nerves in
controlling the voluntary control of micturition and the
pathogenesis of functional LUT diseases [2]. The aim of this
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review is to critically appraise the current knowledge about the
role of TRP channels in LUT dysfunction and their potential
as targets for new drug therapies.
TRPV1
TRPV1, also known as the vanilloid receptor type 1, was
identiﬁed as a heat-sensitive ion channel that can also be
activated by capsaicin, the pungent compound of ‘hot’ chilli
peppers [3]. TRPV1 is highly expressed in unmyelinated, small
diameter sensory ﬁbres (C-ﬁbres) of cranial and spinal nerves
innervating skin, muscles and visceral organs. Activation of
this channel depolarises TRPV1-expressing nociceptive
neurones, causing a painful, burning sensation. Moreover,
these sensory neurones will release pro-inﬂammatory
neuropeptides [calcitonin gene-related peptide (CGRP),
substance P, neurokinins] inducing so-called neurogenic
inﬂammation [4].
The channel is activated by a myriad of stimuli, including
heat, extracellular acidiﬁcation and binding of speciﬁc
endogenous (anandamide, N-arachidonoyl) or exogenous
ligands [capsaicin, resiniferatoxin (RTX)], making it a
molecular integrator of multiple noxious stimuli [1].
TRPV1 in the LUT
TRPV1 is highly expressed in C-ﬁbres innervating the urinary
bladder and urethra in several mammals including rats [5],
mice [6] and humans [7].
Although it has been suggested that TRPV1 is also expressed
in non-neuronal cell types [8], the functional expression of
TRPV1 in the urothelium is very controversial. Initial reports
described TRPV1 expression and functional TRPV1 responses
in isolated urothelial cells from mice [8], rats [9] and humans
[10]. In contrast, an increasing number of groups have more
recently reported the absence of TRPV1 expression and
functional TRPV1 responses in guinea-pig [8], mouse [11–15]
and human [16] urothelial cells. Moreover, a recent approach
using Trpv1-reporter mice, suggested that TRPV1 expression
was restricted to primary aﬀerent neurones, with no detectable
TRPV1 expression in urothelial cells [17].
There can be multiple reasons for these apparent
contradictions: First, Yu et al. [6] have suggested that TRPV1 is
present on aﬀerent neurones that extend into the urothelium,
but not on the urothelium itself. Secondly, several groups have
reported problems with the speciﬁcity of TRPV1 antibodies
and with non-speciﬁc immunoreactivity of urothelial tissue
[6,18]. Thirdly, diﬀerences in cell culture techniques and
(de)diﬀerentiation of cultured cells could inﬂuence the
expression of TRPV1. Kullman et al. [9] reported considerable
variability between diﬀerent cover slips in the percentage of
urothelial cells that responded to capsaicin, ranging from 0 to
>60%, suggesting an inﬂuence of culture techniques on
functional TRPV1 responses. Finally, species diﬀerences may
also contribute to the apparent diﬀerences between these
groups.
The functional role of TRPV1 in the bladder has been studied
using Trpv–/– mice. In comparison to normal mice, these
Trpv1 knockouts had a higher frequency of non-voiding
bladder contractions and had reduced reﬂex voiding under
anaesthesia, but not in awake animals [19]. Moreover, Trpv–/–
mice exhibit reduced ﬁring of bladder aﬀerents in response
to bladder distension [20], indicating a role for TRPV1 in
controlling the excitability of bladder sensory neurones.
TRPV1 is considered a promising target for functional
disorders of the LUT because (i) activation of TRPV1 induces
pain behaviour and detrusor overactivity (DO) in rodents
[21], (ii) activation of TRPV1 in isolated bladder strips causes
detrusor contraction via the release of neuropeptides and
prostaglandins from aﬀerent C-ﬁbres [22], (iii) Trpv1–/– mice
do not develop cystitis-induced DO and pain behaviour
[23,24], (iv) TRPV1 expression is upregulated during
pathological conditions, such as neurogenic DO (NDO) [25].
Several strategies have been developed to target TRPV1
(Fig. 1): (i) desensitisation of TRPV1 expressing aﬀerents by
TRPV1 agonists, (ii) directly inhibiting TRPV1 by TRPV1
antagonists and (iii) selectively inhibiting depolarisation of
TRPV1-expressing aﬀerents by TRPV1 permeable sodium
(Na+) blockers.
TRPV1 as a Pharmaceutical Target?
Agonists: pre-clinical data
Pharmacological experiments in cats and rats show that the
TRPV1 expressing C-ﬁbres are silent under physiological
conditions but may become activated by bacterial or chemical
irritants in the bladder giving rise to bladder hyperreﬂexia
[26]. Moreover, these C-ﬁbres become active and serve as the
aﬀerent arc for the spinal reﬂex that causes NDO in spinal
cord-injured animals [27]. Interestingly, desensitisation of
these C-ﬁbres by systemic capsaicin treatment was able to
inhibit cystitis-induced detrusor hyperreﬂexia in rats [26] and
to successfully treat NDO in spinal cord-injured cats by
interrupting the pathological reﬂex [28].
Activation of TRPV1 in C-ﬁbres produces a biphasic response
(Fig. 1). The immediate eﬀect is stimulatory with transmission
of sensory impulses from the periphery to the CNS (sensed as
a painful irritation) and a peripheral release from the receptor
terminals of neuropeptides including substance P and
CGRP (leading to detrusor contraction and neurogenic
inﬂammation). After exposure to high concentrations of
capsaicin, aﬀerent C-ﬁbres show long lasting functional
desensitisation and even morphological evidence of structural
damage [27].
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Fig. 1 Different mechanisms of TRPV1 modulation. (a) Short administration of TRPV1 induces desensitisation of the channel via not fully understood
mechanisms including phosphorylation and phosphatidylinositol 4,5-bisphosphate (PIP2) depletion. This desensitisation causes a reduced excitability
of the C-fibre. (b) Long-term administration of a TRPV1 agonist causes structural damage of C-fibres and even ablates them. Prolonged binding of
capsaicin induces pore dilatation, which facilitates the entry of Ca2+ and other large cations leading to cell death. (c) TRPV1 antagonists block
opening of the channel making the C-fibres less responsive to TRPV1 activating stimuli. (d) QX-314 enters the C-fibre through the dilated pore of
activated TRPV1 channels when co-administered with a TRPV1 agonist. From within the intracellular compartment QX-314 will block Na+-channels
hereby inhibiting depolarisation of the neurone and afferent signalling from the LUT.
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Clinical development of TRPV1 agonists
Humans have been using capsaicin for thousands of years to
‘spice up’ their diet without long-term side-eﬀects. However,
systemic administration of capsaicin or its ultrapotent
analogue RTX at higher doses induced several undesirable
eﬀects on blood pressure, breathing and other reﬂex pathways
in preclinical models [29]. Therefore, most clinical trials with
TRPV1 agonists have focussed on local delivery methods.
Clinical development of several molecules to target pain relief,
such as Adlea (ALGRX-4957, an injectable preparation of
capsaicin) and Civamide [Zucacapsaicin, a cis-isomer of
capsaicin that can be formulated for oral, nasal or topical
(cream or patch) use] is already in an advanced stadium and
Qutenza® (NGX 4010, capsaicin 8% patch), has recently been
approved by the USA Food and Drug Administration (FDA)
and European Medicines Agency (EMA) for treatment of
post-herpetic neuralgia.
Since the initial description by Maggi et al. [30] about
the use of intravesical capsaicin in humans, several
randomised controlled trials (RCTs) have conﬁrmed the
alleviation of clinical and urodynamic symptoms after
intravesical vanilloid therapy. In a double-blind
placebo-controlled trial comprised of 20 patients with
spinal cord injury with NDO, intravesical instillation of
30 mg capsaicin dissolved in 30% ethanol resulted in a
signiﬁcant improvement in clinical and urodynamic
parameters, with a signiﬁcant decrease in 24-h voiding
frequency and maximum detrusor pressure and an increase
in maximum cystometric capacity [31]. Similar results were
obtained in another RCT, although at the expense of
signiﬁcant initial side-eﬀects, including burning pelvic pain,
sensory urgency, ﬂushes, haematuria and autonomic
hyperreﬂexia [32]. Using capsaicin dissolved in glucidic
solvent instead of ethanol had similar short-term eﬃcacy in
patients with NDO with better tolerance after the instillation
[33]. However, one small placebo-controlled crossover study
did not show a signiﬁcant improvement in NDO after
intravesical capsaicin treatment [34].
In an attempt to improve eﬃcacy and reduce side-eﬀects,
the ultra-potent TRPV1 agonist RTX has also been tested
in several clinical trials. Two RCTs showed signiﬁcant
improvement in bladder capacity and incontinence grade in
neurologically impaired patients with RTX compared with
placebo [35,36]. Two RCTs comparing RTX vs capsaicin
reported improved long-term eﬃcacy [37], less adverse events
and superior urodynamic and clinical improvement with RTX
[38]. However, it should be remarked that, due to lack of
stable formulations, RTX solutions diﬀered amongst the
aforementioned RCTs, which may have inﬂuenced the
outcomes [39,40].
In conclusion, intravesical vanilloids appear to improve
symptoms in ≈80% of patients with NDO but produce
signiﬁcant adverse eﬀects [41,42]. The side-eﬀect proﬁle, the
problems with stability of certain formulations and the success
of other therapies such as intradetrusor injections of
botulinum toxin have hampered the commercialisation and
widespread use of intravesical therapy in clinical practise.
Nevertheless, this therapy remains a valid option in therapy
resistant NDO.
Intravesical vanilloids have also been tested as treatment for
interstitial cystitis/painful bladder syndrome (IC/PBlS).
Capsaicin did not signiﬁcantly improve pain scores in
patients with severe pelvic pain compared with placebo
[43]. Similarly, a single administration of RTX did not
signiﬁcantly improve symptoms in a double-blinded RCT
with 163 patients with IC [44]. In contrast, a recent pilot
study showed that combined therapy of hydrodistention with
intravesical RTX signiﬁcantly relieved pain in patients with
IC/PBlS [45].
Two RCTs have tested the eﬀects of RTX in patients with
idiopathic DO (IDO). One study showed a signiﬁcant
reduction of grade of incontinence after multiple RTX
instillations [46], but the other showed no signiﬁcant
improvement in women with IDO and urgency incontinence
[47]. In patients with overactive bladder with refractory
urgency, instillation of a single dose RTX resulted in a
signiﬁcantly decreased number of frequency episodes and a
subjective improvement in symptoms in 69% of patients [48].
Thus, despite good results in the treatment of NDO, the
eﬃcacy of TRPV1 agonists in the treatment of IC/PBlS and
IDO remains debatable.
Antagonists: pre-clinical data
The eﬀects of TRPV1-desensitising agonists and TRPV1
antagonists are not equivalent. Agonists do not merely
desensitise TRPV1 channels, but also desensitise or even
ablate TRPV1-expressing neurones (Fig. 1), whereas TRPV1
antagonists selectively inhibit TRPV1 activation. This implies
that not only the therapeutic eﬀect but also the side-eﬀect
proﬁle is diﬀerent between both classes of drugs.
In several animal models of LUT dysfunction, selective TRPV1
antagonists have proven to be promising candidates for drug
therapy. GRC6211, an oral TRPV1 antagonist, reduced bladder
hyperactivity in mice with lipopolysaccharide (a bacterial
toxin)-induced cystitis [49] and in rats with NDO after spinal
cord injury [50]. In rats, JTS653, another selective TRPV1
antagonist, attenuated acetic acid-induced bladder overactivity
and blocks aﬀerent neuronal transmission [51]. Similarly,
systemic administration of JNJ17203212 increased the volume
threshold for micturition in rats and inhibited both capsaicin
and citric acid-induced DO [52].
Unfortunately, it became rapidly clear that the ﬁrst generation
of TRPV1 antagonists cause an increase in body temperature
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(hyperthermia), both in animal models and in humans.
Hyperthermia is an on-target eﬀect, reﬂecting that TRPV1 is
tonically active and plays a key role in body temperature
regulation [29].
Clinical development of TRPV1 antagonists
In contrast to the relative lack of interest in TRPV1 agonists,
pharmaceutical companies have very extensively pursued
pharmacological blockade of TRPV1. However, despite the
initial excitement only a few of these antagonists have
advanced to clinical trials, since a Phase II study with
AMG517 was discontinued because of marked and persistent
hyperthermia (up to 39 °C) after exposure to single doses of
this potent antagonist [53].
Similarly, XEND0501, an oral TRPV1 antagonist that was
developed as a novel therapy for overactive bladder, was
well tolerated in a Phase I clinical trial, but also provoked a
dose-related increase in body temperature [54]. Unfortunately,
due to early termination of most of these trials, the clinical
eﬀect of TRPV1 antagonists on pain or on bladder overactivity
remains elusive.
Eﬀorts to develop so called ‘second generation’ TRPV1
antagonists that do not block all modalities (activation by
capsaicin, heat and low pH) of TRPV1, but selectively inhibit
capsaicin activation have been reported not to increase body
temperature [55]. The therapeutic eﬀects of these new
generation TRPV1 antagonists on pain perception or bladder
function are still unknown. Alternatively, intravesical
administration of TRPV1 antagonists might be a way to
overcome systemic side-eﬀects, although data about the
eﬃcacy of intravesical TRPV1 antagonists are currently
lacking.
TRPV1 permeable Na+ channel blockers
Recently, a novel strategy has successfully been used in
rodents to selectively block TRPV1-expressing nociceptors.
In this approach, TRPV1 is used as an ‘entry gate’ rather than
the ‘end-target’. QX-314, a positively charged derivative of
lidocaine has no eﬀect on neuronal Na+ channels when
applied extracellularly (as it cannot inﬁltrate lipid membranes)
but does block Na+ channels when applied intracellularly.
Interestingly, when QX-314 is co-applied with capsaicin, it
permeates inside the cell through activated TRPV1 channels
and thus blocks Na+ channels only in capsaicin-sensitive
nociceptive aﬀerents. This approach was successfully used to
produce prolonged local anaesthesia to mechanical and
thermal noxious stimuli in rats [56]. In eﬀorts to avoid
capsaicin-mediated nociceptive behaviour, anaesthetic agents
with TRPV1-activating properties, such as isoﬂurane and
lidocaine, have successfully been used to produce prolonged
nociceptor-selective block when co-applied with QX-314
[57,58]. A recent study in rats showed that a triple cocktail of
capsaicin, lidocaine and XQ-314 induced a near complete
blockade of incision-induced hypersensitivity for several days,
hereby conﬁrming the clinical potential of this approach.
However, this cocktail produced delayed mechanical
hypersensitivity for several weeks due to neurotoxicity,
underscoring the importance of appropriate safety screening
of these new drug combinations, as safe doses of local
anaesthetics may be toxic in combination with TRPV1 ion
channel activators [59].
This approach appears very promising to attack LUT
dysfunction with increased C-ﬁbre activity, including NDO
and PBlS, but must ﬁrst be shown to be eﬀective and safe in
animal models and humans.
TRPV4
TRPV4 is a multimodal cellular sensor that can be activated
by diverse physical and chemical stimuli, including moderate
heat, cell swelling and binding of endo- and exogenous
chemical ligands [60]. TRPV4 is expressed in numerous
human tissues where it has a versatile role including
mucociliary transport in cilia of the fallopian tubes and
airways, bone remodelling in osteoclasts, osmoregulation in
neurones of the circumventricular organs in the brain, and
vascular function in endothelial cells [60]. Mutations in the
TRPV4 gene are causative for several hereditary neuropathies
and skeletal dysplasias, such as Charcot-Marie-Tooth disease
type 2C, congenital distal spinal motor neuropathy and
brachyolmia type 3 [60].
TRPV4 in the LUT
Functional TRPV4 expression has been shown in bladder
urothelial cells in mice, rats, guinea-pigs and humans
[9,12,61,62]. TRPV4 is located predominantly on the surface
of the basal urothelial cell layers, in close proximity to the
adherence junctions [60,61]. Lower levels of TRPV4
expression have also been detected in detrusor smooth muscle
in mice and sensory nerve ﬁbres [63].
In vitro experiments on cultured urothelial cells showed that
cells from Trpv4–/– mice had attenuated Ca2+-inﬂux and ATP
release in response to stretch compared with cells from
control mice [14]. Moreover, isolated Trpv4–/– bladders showed
reduced stretch-evoked ATP release [61].
In vivo, mice lacking the functional TRPV4 protein exhibit an
abnormal voiding pattern and a lower frequency of voiding
contractions compared with controls [61]. Moreover,
intravesical infusion of GSK1016790A, a potent TRPV4
agonist is able to induce increased aﬀerent ﬁring of
capsaicin-insensitive C-ﬁbres and bladder hyperactivity in
rodents [63,64], whereas, pharmacological blockade of TRPV4
by systemic administration of the TRPV4 antagonist
HC067047 increases bladder capacity and reduces micturition
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frequency in mice [65]. These ﬁndings support the hypothesis
that TRPV4 acts as a mechano-sensor in urothelial cells that
communicate with the underlying aﬀerent nerves [60]. In a rat
model of stress-induced bladder dysfunction, rats that were
exposed to 7 days of repeated variate stress had a signiﬁcantly
smaller bladder capacity and an increased urinary frequency.
In these rats, TRPV4 expression was signiﬁcantly elevated at
the mRNA and protein level in urothelium, but not in
detrusor tissue [66].
Interestingly, patients with Charcot-Marie-Tooth disease type
2C caused by gain of function mutations in the TRPV4 gene
have a high incidence of urinary urgency and incontinence
[67]. It is unclear whether these overactive bladder symptoms
are a consequence of increased TRPV4 activity or of the
neurological disease.
TRPV4 as a Pharmaceutical Target?
Several pharmaceutical companies have patented
TRPV4-targeted drugs for various diseases, but to date no
clinical studies have been reported [68].
TRPV4 agonists
Intravesical instillation of the TRPV4 agonist GSK1016790A
induced detrusor hyperactivity by selective activation of
TRPV4 in mice [63]. Moreover, this drug is able to increase
the contractility of isolated detrusor strips from rats with
experimentally induced detrusor underactivity [69].
Unfortunately, systemic administration of GSK1016790A
causes endothelial dysfunction with profound circulatory
collapse and death in rodents [70]. Therefore further
development of TRPV4 agonists has been abandoned.
TRPV4 antagonists
TRPV4 inhibitors may represent an interesting drug class
for the treatment of LUT storage disorders. Systemic
administration of HC067047, a selective antagonist of TRPV4,
signiﬁcantly reduced pollakisuria and increased the functional
bladder capacity in rats and mice with cyclophosphamide-
induced cystitis. HC067047 has similar eﬀects in healthy
animals, but the eﬀects were signiﬁcantly smaller, supporting
a role for TRPV4 in the development of cystitis-induced
bladder hyperactivity [65]. Moreover, intravesical
administration of HC067047 signiﬁcantly reduced the
urinary frequency in rats with repeated variate stress-induced
bladder dysfunction [66].
Interestingly, no signiﬁcant eﬀects of systemic treatment with
HC067047 on various parameters, including core body
temperature, heart rate, locomotion, motor coordination, ﬂuid
intake, or thermal selection behaviour were detected,
suggesting these drugs have a good side-eﬀect proﬁle [65].
Similarly, systematic administration of GSK2193874, another
selective orally available TRPV4 blocker, had no signiﬁcant
adverse eﬀects in a rodent model for heart failure [71].
GlaxoSmithKline very recently published the protocol of the
ﬁrst Phase I clinical trial with a systemic TRPV4 antagonist
(GSK2798745) to test its safety and tolerability in healthy
subjects and patients with stable heart failure. Results of this
study are awaited eagerly [72].
TRPM8
TRPM8 was identiﬁed as a marker of prostate cancer, before it
was described as a sensory ion channel belonging to the TRP
superfamily. TRPM8 activity is increased by cool temperatures
(8–25 °C) and by chemicals that provoke ‘cool’ sensations,
such as menthol and icilin. G proteins, lipid messengers and
polyunsaturated fatty acids also modulate TRPM8 activity
[73]. As a cold sensor in the body, TRPM8 is predominantly
expressed in a small subpopulation of dorsal root ganglion
(DRG) and trigeminal neurones that do not express TRPV1
[73].
TRPM8 in the LUT
TRPM8 expression was shown in a subset of small ﬁbres from
S2–S4 DRG neurones that innervate the LUT in human [74]
and rat [75]. Despite earlier reports of urothelial TRPM8
expression in rats [9] and humans [76], TRPM8 expression in
urothelium remains highly controversial. Several recent
studies were unable to detect TRPM8 mRNA, protein or
functional responses in mouse [6,12,14] and human [16]
urothelium.
Intravesical infusion of the TRPM8 agonist menthol facilitates
the micturition reﬂex in guinea-pigs and rats [77,78] and
sensitised the bladder to infusion of cold (4 °C) saline [77].
Conversely, pharmacological blockade of TRPM8 decreased
the frequency of volume-induced bladder contractions in rats
[79].
As a cold sensor, TRPM8 has been suggested to play a role in
the ice-water test [77,80]. In the pre-MRI era, this test was
used to determine the level of neural injury in patients
with NDO. Instillation of ice-cold water evoked bladder
contractions in patients with upper but not with lower motor
neurone lesions [81]. Importantly, all these publications used
menthol as a TRPM8 speciﬁc agonist. Nevertheless, it has
been clearly shown that menthol is not a speciﬁc agonist for
TRPM8 but also activates the noxious cold sensor TRPA1 and
other cellular targets [82,83].
It is well known that cold weather can precipitate urinary
urgency symptoms in patients [84]. Similarly, environmental
cold induces DO in rats and this eﬀect is counteracted by
systemic administration of BCTC, a TRPM8 selective channel
antagonist [85].
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TRPM8 as a Pharmaceutical Target?
TRPM8 agonists
TRPM8 agonists are considered important therapeutic
compounds for attenuating pain and inducing apoptosis of
cancer cells expressing TRPM8. Menthol-containing capsules
are currently being tested in a Phase III trial as treatment for
hypertension, whereas a menthol-containing cream will go
into Phase III testing for pain relief of osteoarthritis [68].
D3263, an orally bioavailable TRPM8 agonist developed by
Dendreon, inhibits the growth of tumour cells expressing
TRPM8 in vitro. This compound has already completed
Phase I testing and the company recently announced the
initiation of clinical studies on patients with advanced solid
tumours [68].
Based on the observation that TRPM8 activation facilitates the
micturition reﬂex [77,78], TRPM8 agonists may be beneﬁcial
in patients with detrusor underactivity. However, currently
there is no strong evidence to support this strategy.
TRPM8 antagonists
Several pharmaceutical companies have made tremendous
eﬀorts in the development of TRPM8 antagonists as
analgesics, antitumor agents and for the treatment of
overactive bladder [68]. In preclinical studies, TRPM8
antagonists reduce cold stress-induced DO in rats and
decrease voiding frequency in rats with cyclophosphamide-
induced cystitis [85,86]. In contrast to TRPV1 antagonists,
pharmacological blockade of TRPM8 causes hypothermia in
rodents [87]. To date, none of these TRPM8 antagonists has
made it to clinical trials.
TRPA1
TRPA1 functions as a broadly tuned sensor for noxious
stimuli in a subpopulation of TRPV1-expressing primary
aﬀerent nociceptive neurones. The channel can be activated by
a myriad of stimuli, such as intracellular Ca2+ and Zn2+,
noxious cold temperature (<17 °C) and a wide variety of
chemical irritants [88].
TRPA1 in the LUT
Recently, there has been great interest in the functional role of
TRPA1 in the urinary bladder, the intestine and the colon. As
a mediator of inﬂammation and pain, TRPA1 is considered a
potential target in the treatment of visceral hypersensitivity
syndromes, e.g. inﬂammatory bowel disease, PBlS and
overactive bladder. In the bladder, TRPA1 channels are
expressed in sensory nerve endings from lumbosacral DRG
neurones, but not in the urothelial cells [6,12,14,88].
TRPA1-expressing C-ﬁbres constitute ≈50% of all
bladder-innervating sensory neurones and mostly express
CGRP, substance P and TRPV1.
TRPA1 functions as a sensor of noxious stimuli in the
bladder. Intravesical instillation of TRPA1 agonists, e.g. allyl
isothiocynate or cinnamaldehyde, stimulates bladder
emptying by inducing urinary frequency in vivo [89,90]. This
is supported by in vitro experiments showing that TRPA1
agonists cause a graded contraction of rat urinary bladder
strips [91] but induce relaxation of phenylephrine
pre-contracted urethral muscle strips [92]. Interestingly,
TRPA1 can be activated by acrolein, the metabolite of the
chemotherapeutic drug cyclophosphamide that is responsible
for inducing haemorrhagic cystitis. Thus, TRPA1 may, at
least in part, be responsible for the development of
haemorrhagic cystitis in patients with cancer treated with
cyclophosphamide. Bacterial toxins and metabolites, e.g.
lipopolysaccharides and H2S, have recently been shown to
activate TRPA1, suggesting that TRPA1 also plays a role in
the early detection and elimination of urinary pathogens
[93]. In addition, we recently reported that TRPA1, rather
than TRPM8 might be the actual cold sensor in the bladder
cooling reﬂex [94].
TRPA1 as a Pharmaceutical Target?
TRPA1 antagonists
Pharmaceutical companies have patented multiple TRPA1
antagonists. Although these drugs show eﬃcacy in various
animal models for pain and hyperalgesia, they await clinical
validation [68]. One compound, GRC17536, has successfully
completed a Phase I clinical trial and a Phase II clinical trial in
patients with refractory chronic cough is currently ongoing
[95].
Another TRPA1 antagonist, HC030031, has been proven
eﬀective to ameliorate cystometric parameters in rats with
NDO after spinal cord injury. In these rats, TRPA1 expression
in DRG ganglia was upregulated at the protein and mRNA
level and the eﬀects of the TRPA1 antagonists could be
mimicked by TRPA1 RNA knockdown [96]. In a visceral pain
model, using cyclophosphamide-induced cystitis, HC030031
eﬀectively alleviated cystitis induced bladder hyperalgesia [97].
The plethora of TRPA1 antagonists still awaits clinical
validation.
Other TRP Channels in the LUT
In addition to the TRP channels discussed above, many other
TRP channels are expressed throughout the bladder wall. In
the urothelium of mice, mRNA expression of 22 diﬀerent
TRP channels could be detected, albeit at variable levels [6].
TRPV2, a close relative of TRPV1, is expressed in murine, rat
and human urothelial cells [12,19,98]; however, the exact
physiological role remains poorly understood due to lack of
speciﬁc pharmacology and antibodies. TRPM4 is expressed at
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the apical membrane of umbrella cells and in rat detrusor cells
where they may regulate smooth muscle excitability and
contractility [99]. Also functional TRPM7 expression has been
demonstrated in mouse and human urothelial cells [12,16],
although the functional role of this ubiquitously expressed ion
channel remains elusive.
Conclusions
At the beginning of the new millennium the scientiﬁc and
medical world was ‘high’ on TRP channels, as this new ion
channel family emerged as an exciting new therapeutic target.
Since then, a lot of scientiﬁc, industrial and clinical eﬀort has
Fig. 2 Examples of TRP channel modulating compounds with potential to treat DO and their stage of development.
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been put into the characterisation and pharmaceutical
targeting of TRP channels.
Although it is clear that several TRP channels play key roles in
normal and pathological LUT physiology, many questions and
controversies remain about their exact localisation, structure
and function. The main reasons for these apparent diﬃculties
are a lack of antibody and (ant)agonist speciﬁcity,
methodological variability and interspecies diﬀerences,
inherent to the relative youth of this research ﬁeld.
In recent years, a large constellation of compounds has been
developed that target TRP channels and, although therapeutic
indications are numerous, only a few of them have advanced
into clinical trials. TRPV1 is by far the best pupil in the
class with the recent FDA approval of the TRPV1 agonist,
capsaicin, to treat post-herpetic neuralgia. For the treatment
of LUT diseases the clinical breakthrough of TRP channel
modulation is still awaited, notwithstanding that TRPV1
agonists have shown good eﬃcacy in patients with NDO. The
ﬁrst generation of TRPV1 antagonists suﬀered from their
side-eﬀect proﬁle, inducing hyperthermia, but a new
generation of antagonists is being developed to tackle these
problems. These insights can assist further development of
other TRP (ant)agonists. Alternatively, intravesically applied
TRP-targeting drugs may be used to minimise these systemic
adverse events. Compounds modulating other TRP channels
in the LUT (TRPV4, TRPM8 and TRPA1) are currently being
tested in pre-clinical studies and Phase I clinical trials (Fig. 2)
[30–36,49–52,54,56–58,65,66,71,85,86,95–97], so hopefully
these TRP channel modulators can realise the expectations of
becoming truly revolutionary pharmacotherapies.
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